New Delhi News

Amyotrophic Lateral Sclerosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Amyotrophic Lateral Sclerosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 17
16:57 2021
Amyotrophic Lateral Sclerosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Amyotrophic Lateral Sclerosis (ALS) – Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Amyotrophic Lateral Sclerosis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Amyotrophic Lateral Sclerosis pipeline landscapes. 

The report comprises Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Amyotrophic Lateral Sclerosis pipeline products.    

 

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. 

Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Orion Pharma, Brainstorm-Cell Therapeutics, Orphazyme, MediciNova, Biogen, Biohaven Pharmaceutical, Prilenia Therapeutics, Apellis Pharmaceuticals, etc., are developing therapies for the treatment of Amyotrophic Lateral Sclerosis.

  • Emerging therapies such as Levosimendan, NurOwn, Arimoclomol, Ibudilast, Tofersen, Verdiperstat, Pridopidine, AMX0035, Pegcetacoplan, are expected to have a significant impact on the  Amyotrophic Lateral Sclerosis market in the coming years.

Get an overview of pipeline landscape @ Amyotrophic Lateral Sclerosis Clinical Trials Analysis 

Amyotrophic Lateral Sclerosis Pipeline Therapies along with Key Players:

  • Levosimendan: Orion Pharma

  • NurOwn: Brainstorm-Cell Therapeutics

  • Arimoclomol: Orphazyme

  • Ibudilast: MediciNova

  • Tofersen: Biogen

  • Verdiperstat: Biohaven Pharmaceutical

  • Pridopidine: Prilenia Therapeutics

  • AMX0035: Amylyx

  • Pegcetacoplan: Apellis Pharmaceuticals

Scope of Amyotrophic Lateral Sclerosis Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Orion Pharma, Brainstorm-Cell Therapeutics, Orphazyme, MediciNova, Biogen, Biohaven Pharmaceutical, Prilenia Therapeutics, Apellis Pharmaceuticals, and others.

  • Pipeline Therapies: Levosimendan, NurOwn, Arimoclomol, Ibudilast, Tofersen, Verdiperstat, Pridopidine, AMX0035, Pegcetacoplan, and others.

Table of Contents

1

Amyotrophic Lateral Sclerosis Report Introduction

2

Amyotrophic Lateral Sclerosis Executive Summary

3

Amyotrophic Lateral Sclerosis Overview

4

Amyotrophic Lateral Sclerosis- Analytical Perspective In-depth Commercial Assessment

5

Amyotrophic Lateral Sclerosis Pipeline Therapeutics

6

Amyotrophic Lateral Sclerosis Late Stage Products (Phase II/III)

7

Amyotrophic Lateral Sclerosis Mid Stage Products (Phase II)

8

Amyotrophic Lateral Sclerosis Early Stage Products (Phase I)

9

Amyotrophic Lateral Sclerosis Preclinical Stage Products

10

Amyotrophic Lateral Sclerosis Therapeutics Assessment

11

Amyotrophic Lateral Sclerosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Amyotrophic Lateral Sclerosis Key Companies

14

Amyotrophic Lateral Sclerosis Key Products

15

Amyotrophic Lateral Sclerosis Unmet Needs

16 

Amyotrophic Lateral Sclerosis Market Drivers and Barriers

17

Amyotrophic Lateral Sclerosis Future Perspectives and Conclusion

18

Amyotrophic Lateral Sclerosis Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Amyotrophic Lateral Sclerosis Drugs Pipeline Report.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles